Pyrls

The 2026 GINA Report is here, with several notable updates to asthma management guidance:

What’s new: 1,000+ NAPLEX-style practice questions Practice Mode: • Build custom quizzes with 10–500 questions • Study by domain, topic, or missed questions • Choose timed or untimed sessions • Review explanations after every question Full Mock Exam: • 225 exam-weighted questions • 6-hour realistic simulation • Forward-only navigation • Detailed competency reports • Resume unfinished sessions Limited-time launch offer: Get 12 months of unlimited NAPLEX Prep for $50, regularly $100. Available now at pyrls.com.

Massive update to the Pyrls NAPLEX Virtual Testing Center. 1,000+ practice questions, a new Practice Mode, updated full mock exams, realistic timing, and more (see next tweet). Included for Pyrls Pro members + new NAPLEX-only option now available at pyrls.com.

FDA Approves UTEBZI (tebipenem pivoxil), the First Oral Carbapenem for Complicated UTI Treatment

FDA Approves Q8W Dosing Regimen for EBGLYSS (lebrikizumab-lbkz)

FDA Approves ZAYNICH (cefepime/zidebactam) for Complicated UTI Treatment

We released our new Dyslipidemia Pharmacotherapy Review, which includes recommendations from the 2026 ACC/AHA/Multisociety Guideline! ✨ Find the full review and pharmacotherapy chart in the Pyrls mobile app and at pyrls.com. 📱

New FDA approval! ✨ BAXFENDY (baxdrostat) is now approved for adults with hypertension not adequately controlled on other agents.

New FDA approval: TRIMBOW is now approved as another ICS/LABA/LAMA option for maintenance treatment of asthma in adults. ✨

Charts!!!

We’ve updated our insulin products chart to include Awiqli and Langlara for an at-a-glance comparison of insulin options. ✨ Find this full chart and more pharmacotherapy resources in the Pyrls mobile app and at pyrls.com. 📱

We will be attending the @PQAAlliance Annual Meeting next week in Baltimore! We’re looking forward to showing members how Pyrls is helping modernize drug information for teams across pharmacy, MTM, and healthcare quality. Stop by the Industry Showcase and say hi! #PQA26 #MTM

Our team is actively reviewing the new guidance and updating key Pyrls resources, including our Asthma Management chart, to reflect these changes. Stay tuned in the Pyrls app and at pyrls.com for updated clinical pearls and refreshed asthma tools. ✨

The 2026 GINA Report is here, with several notable updates to asthma management guidance:

The Pyrls app includes: - Drug summaries - Drug interaction checker - Pharmacotherapy reviews - Pill identifier - Pill counter (yes the app can count pills!) - Clinical charts and tables - And more Built for pharmacy students, pharmacists, clinicians, and anyone who needs access to practical medication information. Available on iOS and Android! 📱

A lot of you follow Pyrls for drug news, charts, and pharmacy education. But many of you still do not know we have an app that’s free to download!

FDA Approves FOUNDAYO (orforglipron), an Oral GLP-1 Receptor Agonist, for Weight Loss

We’ve got a booth at @pharmacists APhA Annual! If you’re here, come say hi in the exhibit hall and get a free digital business card powered by @HelixCardApp. We’ll also have pharmacotherapy charts, and of course, pens! Hope to see you there! 💜

The FDA just approved the first true generic Flovent HFA inhaler, potentially reshaping access and pricing for millions of asthma patients. Read more: rxradio.fm/drug-pricing-a…

Zepbound (tirzepatide) Now Available in Multi-Dose KwikPen

FDA Approves BYSANTI (milsaperidone) for the Treatment of Schizophrenia and Bipolar I Disorder